China's Polyene Phosphatidyl Choline Market Investigation Report 2010-2019

Aug 17, 2015, 08:10 ET from Research and Markets

DUBLIN, Aug. 17, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/4vn56h/investigation) has announced the addition of the "Investigation Report on China's Polyene Phosphatidyl Choline Market, 2010-2019" report to their offering.

China is recognized worldwide as one of the countries with a high incidence of liver disease. Viral hepatitis, fatty liver, alcoholic liver disease, medicamentous liver lesion and liver cancer have posed a severe threat to the Chinese people's health. In recent years, drugs for liver disease that rank second to proton pump inhibitor in drugs for the digestive system have gradually become a variety with large sales value which occupies 30% of the total sales value of all ten categories of drugs for digestive system.

Among all the drugs for liver disease, polyene phosphatidyl choline is the natural diglyceride of cholinephosphoric acid and unsaturated fatty acids which can protect hepatocyte from lesion, alleviate inflammation reaction and improve the detoxification of the liver. And it is used for the treatment of hepatitis (acute and chronic), hepatic cirrhosis and poisoning with certain efficacy in the clinic. First developed by Sanofi, polyene phosphatidyl choline has been marketed under the trade name of Essentiale Forte.

Some local enterprises are already capable of producing polyene phosphatidyl choline APIs and injections. For example, Sichuan Haisco Pharmaceutical Co., Ltd and Chengdu Tiantaishan Pharmaceutical Co., Ltd have been approved to produce polyene phosphatidyl choline under the trade name of Yibisheng. Imported drugs mainly come from Sanofi (Beijing), Shenzhen Sanofi Pasteur Biological Products Co., Ltd, Sanofi-Aventis Ukraine LLc and A.Nattermann & Cie.GmbH.

The growth of polyene phosphatidyl choline has accelerated since 2006, making it occupy an important proportion of the adjuvant drugs for liver disease. According to this survey, the sales value of polyene phosphatidyl choline in sample hospitals rose from less than CNY 60 million in 2005 to over CNY 400 million in 2014 and CAGR during this period reached 25%.

With the lifestyle changes brought about by economic development, the incidence of liver disease in China has kept increasing. Therefore, the market size of polyene phosphatidyl choline is expected to continue to grow in the next few years in China.

Key Topics Covered:

1 Related Concepts of Polyene Phosphatidyl Choline

2 Market Profile of Polyene Phosphatidyl Choline in China

3 Survey on Sales Status of Polyene Phosphatidyl Choline in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Polyene Phosphatidyl Choline in China, 2010-2014

5 Survey on Dosage Forms of Polyene Phosphatidyl Choline in China, 2010-2014

6 Reference Price of Polyene Phosphatidyl Choline in Chinese Hospitals in 2014

7 Major Manufacturers of Polyene Phosphatidyl Choline in Chinese Market, 2010-2014

8 Market Outlook of Polyene Phosphatidyl Choline in China, 2015-2019

Companies Mentioned

- Shenzhen Sanofi Pasteur Biological Products Co., Ltd

- Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd

- Chengdu Tiantaishan Pharmaceutical Co., Ltd

- Aventis Pharma S.p.A.

For more information visit

http://www.researchandmarkets.com/research/4vn56h/investigation

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com